Grifols announces an increase in copay assistance for Xembify (immune globulin subcutaneous human-klhw), a 20% subcutaneous immunoglobulin therapy for the treatment of patients 2 years of age and older with primary immunodeficiency disease. The increase doubles the amount provided from $5,000 to $10,000 per calendar year, and eligible patients may pay as little as $0 for Xembify treatment. In addition to the increase in the copay assistance program, Grifols offers Patient Assistance, a program for uninsured patients, through the Xembify Connexions patient support program.

Grifols